July 31, 2016 1:48 AM ET

Biotechnology

Company Overview of Nuo Therapeutics, Inc.

Company Overview

Nuo Therapeutics, Inc., a biomedical company, provides biodynamic therapies for wound care in the United States and internationally. Its flagship product is Aurix system, a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of various wounds. The company also offers Angel Concentrated Platelet Rich Plasma System, a multi-functional cell separation device, which produces concentrated platelet rich plasma for use in the operating room and clinic, as well as in a range of orthopedic and cardiovascular indications; ancillary products, such as phlebotomy and applicator supplies; and activAT, which produces autologous thrombin serum from platelet poor ...

207A Perry Parkway

Suite 1

Gaithersburg, MD 20877

United States

Founded in 1987

46 Employees

Phone:

240-499-2680

Fax:

240-499-2690

Key Executives for Nuo Therapeutics, Inc.

Chief Executive Officer, Chief Financial Officer and Executive Director
Age: 54
Head of Comprehensive Clinical Trial Data Audit
Chief Science Officer
Age: 50
Chief Restructuring Officer
Director of Quality Assurance and Regulatory Affairs
Compensation as of Fiscal Year 2016.

Nuo Therapeutics, Inc. Key Developments

Nuo Therapeutics, Inc. Appoints David E. Jorden as Chief Executive Officer and Chief Financial Officer

The Board of Directors of Nuo Therapeutics, Inc. on July 1, 2016 elected David E. Jorden as Chief Executive Officer and Chief Financial Officer of the company. Mr. Jorden had previously served as the company’s Acting Chief Executive Officer and Acting Chief Financial Officer.

Nuo Therapeutics, Inc. Engages CohnReznick LLP as Independent Registered Public Accounting Firm

On June 15, 2016, the Audit Committee of the Board of Directors of Nuo Therapeutics, Inc. engaged CohnReznick LLP as the company’s independent registered public accounting firm for the company’s fiscal year ended December 31, 2015.

Stegman & Company Resigns as Independent Registered Public Accounting Firm of Nuo Therapeutics, Inc

Nuo Therapeutics, Inc.'s independent registered public accounting firm, Stegman & Company announced that effective June 1, 2016 substantially all directors and employees of Stegman have joined Dixon Hughes Goodman LLP. As a result, effective June 1, 2016 Stegman resigned as the company's independent registered public accounting firm. A successor independent registered public accounting firm has not yet been engaged by the company as of the date of this filing.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 5, 2016
--
Bankruptcy
January 26, 2016
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nuo Therapeutics, Inc., please visit www.nuot.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.